These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7740055)

  • 1. Reinforcing effects of triazolam in sedative abusers: correlation of drug liking and self-administration measures.
    Roache JD; Meisch RA; Henningfield JE; Jaffe JH; Klein S; Sampson A
    Pharmacol Biochem Behav; 1995 Feb; 50(2):171-9. PubMed ID: 7740055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diazepam and triazolam self-administration in sedative abusers: concordance of subject ratings, performance and drug self-administration.
    Roache JD; Griffiths RR
    Psychopharmacology (Berl); 1989; 99(3):309-15. PubMed ID: 2594898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers.
    Mintzer MZ; Griffiths RR
    Behav Pharmacol; 2005 Nov; 16(7):579-84. PubMed ID: 16170235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flunitrazepam and triazolam: a comparison of behavioral effects and abuse liability.
    Mintzer MZ; Griffiths RR
    Drug Alcohol Depend; 1998 Dec; 53(1):49-66. PubMed ID: 10933340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative abuse liability of indiplon and triazolam in humans: a comparison of psychomotor, subjective, and cognitive effects.
    Carter LP; Griffiths RR; Suess PE; Casada JH; Wallace CL; Roache JD
    J Pharmacol Exp Ther; 2007 Aug; 322(2):749-59. PubMed ID: 17502431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of preference for nightly triazolam versus placebo in moderate social alcohol drinkers.
    Mintzer MZ; Allen RP; Griffiths RR
    J Psychopharmacol; 2001 Mar; 15(1):3-8. PubMed ID: 11277606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nighttime versus daytime hypnotic self-administration.
    Roehrs T; Bonahoom A; Pedrosi B; Zorick F; Roth T
    Psychopharmacology (Berl); 2002 May; 161(2):137-42. PubMed ID: 11981593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
    Johnson MW; Suess PE; Griffiths RR
    Arch Gen Psychiatry; 2006 Oct; 63(10):1149-57. PubMed ID: 17015817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypnotic self administration and dose escalation.
    Roehrs T; Pedrosi B; Rosenthal L; Roth T
    Psychopharmacology (Berl); 1996 Sep; 127(2):150-4. PubMed ID: 8888381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of drug reinforcement by behavioral requirements following drug ingestion.
    Silverman K; Kirby KC; Griffiths RR
    Psychopharmacology (Berl); 1994 Mar; 114(2):243-7. PubMed ID: 7838915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypnotic self administration: forced-choice versus single-choice.
    Roehrs T; Pedrosi B; Rosenthal L; Zorick F; Roth T
    Psychopharmacology (Berl); 1997 Sep; 133(2):121-6. PubMed ID: 9342777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of triazolam and pentobarbital: performance impairment, subjective effects and abuse liability.
    Roache JD; Griffiths RR
    J Pharmacol Exp Ther; 1985 Jul; 234(1):120-33. PubMed ID: 2861282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment regimen and hypnotic self-administration.
    Roehrs T; Bonahoom A; Pedrosi B; Rosenthal L; Roth T
    Psychopharmacology (Berl); 2001 Apr; 155(1):11-7. PubMed ID: 11374329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of triazolam on drinking in baboons with and without an oral self-administration history: a reinstatement phenomenon.
    Kautz MA; Ator NA
    Psychopharmacology (Berl); 1995 Nov; 122(2):108-14. PubMed ID: 8848525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reinforcing effects of caffeine in coffee and capsules.
    Griffiths RR; Bigelow GE; Liebson IA
    J Exp Anal Behav; 1989 Sep; 52(2):127-40. PubMed ID: 2794839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative abuse liability of triazolam: experimental assessment in animals and humans.
    Griffiths RR; Lamb RJ; Ator NA; Roache JD; Brady JV
    Neurosci Biobehav Rev; 1985; 9(1):133-51. PubMed ID: 2858078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral self-administration of triazolam, diazepam and ethanol in the baboon: drug reinforcement and benzodiazepine physical dependence.
    Ator NA; Griffiths RR
    Psychopharmacology (Berl); 1992; 108(3):301-12. PubMed ID: 1523281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triazolam-amphetamine interaction: dissociation of effects on memory versus arousal.
    Mintzer MZ; Griffiths RR
    J Psychopharmacol; 2003 Mar; 17(1):17-29. PubMed ID: 12680736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital.
    Zawertailo LA; Busto UE; Kaplan HL; Greenblatt DJ; Sellers EM
    J Clin Psychopharmacol; 2003 Jun; 23(3):269-80. PubMed ID: 12826989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB.
    Carter LP; Richards BD; Mintzer MZ; Griffiths RR
    Neuropsychopharmacology; 2006 Nov; 31(11):2537-51. PubMed ID: 16880774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.